206 related articles for article (PubMed ID: 37586765)
1. TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.
Tvingsholm SA; Frej MS; Rafa VM; Hansen UK; Ormhøj M; Tyron A; Jensen AWP; Kadivar M; Bentzen AK; Munk KK; Aasbjerg GN; Ternander JSH; Heeke C; Tamhane T; Schmess C; Funt SA; Kjeldsen JW; Kverneland AH; Met Ö; Draghi A; Jakobsen SN; Donia M; Marie Svane I; Hadrup SR
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586765
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies.
Stanojevic M; Hont AB; Geiger A; O'Brien S; Ulrey R; Grant M; Datar A; Lee PH; Lang H; Cruz CRY; Hanley PJ; Barrett AJ; Keller MD; Bollard CM
Cytotherapy; 2021 Aug; 23(8):694-703. PubMed ID: 33832817
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition.
Elia AR; Circosta P; Sangiolo D; Bonini C; Gammaitoni L; Mastaglio S; Genovese P; Geuna M; Avolio F; Inghirami G; Tarella C; Cignetti A
Hum Gene Ther; 2015 Apr; 26(4):220-31. PubMed ID: 25758764
[TBL] [Abstract][Full Text] [Related]
4. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
5. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
6. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
Hamieh M; Chatillon JF; Dupel E; Bayeux F; Fauquembergue E; Maby P; Drouet A; Duval-Modeste AB; Adriouch S; Boyer O; Latouche JB
Front Immunol; 2021; 12():674276. PubMed ID: 34566953
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma.
Frøsig TM
Dan Med J; 2015 Aug; 62(8):B5144. PubMed ID: 26239596
[TBL] [Abstract][Full Text] [Related]
8. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.
Bobisse S; Rondina M; Merlo A; Tisato V; Mandruzzato S; Amendola M; Naldini L; Willemsen RA; Debets R; Zanovello P; Rosato A
Cancer Res; 2009 Dec; 69(24):9385-94. PubMed ID: 19996290
[TBL] [Abstract][Full Text] [Related]
9. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
[TBL] [Abstract][Full Text] [Related]
10. Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy.
Simon B; Harrer DC; Thirion C; Schuler-Thurner B; Schuler G; Uslu U
J Immunol Methods; 2019 Sep; 472():55-64. PubMed ID: 31207210
[TBL] [Abstract][Full Text] [Related]
11. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
12. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
13. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
14. Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer.
Matsuzaki J; Lele S; Odunsi K; Tsuji T
Oncoimmunology; 2022; 11(1):2020983. PubMed ID: 35003898
[TBL] [Abstract][Full Text] [Related]
15. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
Yang S; Linette GP; Longerich S; Haluska FG
J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
[TBL] [Abstract][Full Text] [Related]
16. Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
Tucker CG; Mitchell JS; Martinov T; Burbach BJ; Beura LK; Wilson JC; Dwyer AJ; Singh LM; Mescher MF; Fife BT
J Immunol; 2020 Sep; 205(5):1449-1460. PubMed ID: 32737148
[TBL] [Abstract][Full Text] [Related]
17. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
Hu Z; Xia J; Fan W; Wargo J; Yang YG
Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
[TBL] [Abstract][Full Text] [Related]
18. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
[TBL] [Abstract][Full Text] [Related]
19. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
[TBL] [Abstract][Full Text] [Related]
20. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
